CoronaVac COVID-19 vaccine from China needs to be approved by NPRA – Minister

20210227 172221

KUALA LUMPUR FEB.27: The Sinovac’s CoronaVac COVID-19 vaccine that arrived in Malaysia today have to go through a manufacturing process by Pharmaniaga- a phamaceutical company before it could be evaluated and approved by the National Pharmaceutical Regulatory Agency (NPRA).

Coordinating Minister for the National COVID-19 Immunisation Programme, Khairy Jamaluddin said, the manufacturing process is one of the criteria that would be evaluated by NPRA before giving recommendations to the Drug Control Authority (PBKD) for approval.

“Many ask why Malaysia received a vaccine that has yet to be approved by the regulatory agency. This is because the approval process from the regulatory agency must look how this vaccine is bottled before it can be approved.

“Among others, it aims to provide registration application data for carrying out a validation application data for carrying out a validation process, as well as looking at stability data from the factory,” said Khairy at a press conference after witnessing the arrival of 200 litres of CoronaVac vaccine developed by the Chinese pharmaceutical Sinovac at the Kuala Lumpur International Airport (KLIA) from Beijing, China this morning. –Malaysia World News

more recommended stories